At the end of the latest market close, CymaBay Therapeutics Inc. (CBAY) was valued at $2.06. In that particular session, Stock kicked-off at the price of $2.07 while reaching the peak value of $2.4458 and lowest value recorded on the day was $2.03. The stock current value is $2.40.Recently in News on June 22, 2022, CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022. Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival. You can read further details here
CymaBay Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.65 on 01/04/22, with the lowest value was $1.67 for the same time period, recorded on 05/11/22.
CymaBay Therapeutics Inc. (CBAY) full year performance was -46.31%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CymaBay Therapeutics Inc. shares are logging -50.31% during the 52-week period from high price, and 43.70% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.67 and $4.83.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1107782 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the CymaBay Therapeutics Inc. (CBAY) recorded performance in the market was -28.99%, having the revenues showcasing -29.20% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 196.99M, as it employees total of 60 workers.
Market experts do have their say about CymaBay Therapeutics Inc. (CBAY)
During the last month, 0 analysts gave the CymaBay Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.70, with a change in the price was noted -0.37. In a similar fashion, CymaBay Therapeutics Inc. posted a movement of -13.36% for the period of last 100 days, recording 522,477 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CBAY is recording 0.73 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.73.
Technical breakdown of CymaBay Therapeutics Inc. (CBAY)
Raw Stochastic average of CymaBay Therapeutics Inc. in the period of last 50 days is set at 46.20%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 88.06%. In the last 20 days, the company’s Stochastic %K was 49.75% and its Stochastic %D was recorded 33.00%.
Bearing in mind the latest performance of CymaBay Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -28.99%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -32.77%, alongside a downfall of -46.31% for the period of the last 12 months. The shares increased approximately by 19.40% in the 7-day charts and went up by 14.29% in the period of the last 30 days. Common stock shares were lifted by -29.20% during last recorded quarter.